Alzheimer’s trials targeting β-secretase screeched to a halt when it turned out that the drugs slightly worsened cognition. Alarmed, pharmaceutical companies ditched their BACE programs, or put them ...

BACE inhibitors succeeded in stemming the tide of Aβ production in the brain, but the drugs also slightly dulled cognition and shrank the brain, bringing the trials to a screeching halt. Rather than ...

Over the past 15 years, many of the steps in the development of Alzheimer's disease have been elucidated. In particular, the emergence of the amyloid-β (Aβ) peptide as the central molecule in the ...

Johnson & Johnson’s Janssen unit has joined the far-from-exclusive Alzheimer's disease failure club after deciding to terminate trials of its BACE inhibitor atabacestat. This time the decision hasn’t ...

Eli Lilly is dropping a BACE inhibitor that was being tested in Alzheimer’s disease in combination with a second drug, a monoclonal antibody that binds to amyloid deposits in the brain. The news, ...